Abstract
The efficacy of metformin for the treatment of psoriasis: a meta-analysis study
- Department of Paediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
- Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China
Introduction and aim:
Metformin has potential in treating patients with psoriasis, and this meta-analysis aims to explore the impact of metformin supplementation on treatment efficacy for psoriasis.
Material and methods:
The PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of metformin on treatment efficacy for patients with psoriasis.
Results:
Three RCTs were included in the meta-analysis. Overall, compared with control intervention for psoriasis, metformin intervention resulted in significantly increased psoriasis area severity index (PASI) 75% reduction (odds ratio (OR) = 22.02; 95% confidence interval (CI): 2.12 to 228.49; p = 0.01), and erythema, scaling and induration (ESI) 75% reduction (OR = 9.12; 95% CI: 2.13 to 39.02; p = 0.003), and was associated with substantially decreased fasting plasma glucose (FPG, standard mean difference (SMD) = –0.59; 95% CI: –0.92 to –0.26; p = 0.0005), triglycerides (SMD = –0.92; 95% CI: –1.38 to –0.47; p < 0.0001), total cholesterol (SMD = –0.77; 95% CI: –1.22 to –0.32; p = 0.00008), and low-density lipoprotein (LDL, SMD = –0.67; 95% CI: –1.12 to –0.23; p = 0.003).
Conclusions:
Metformin supplementation effectively improves treatment efficacy and metabolic syndrome in psoriasis patients.
Keywords
psoriasis, metformin supplementation, treatment efficacy, meta-analysis
Indexed in
Integrated with
